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Abstract
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
(PhIP) has been implicated as a major mutagenic
heterocyclic amine in thehumandiet and iscarcinogenic
in the rat prostate. To validate PhIP-induced rat prostatic
neoplasia as a model of human prostate cancer pro-
gression, we sought to study the earliest histologic and
morphologic changes in the prostate and to follow
progressive changes over time. We fed sixty-seven
5-week-old male Fischer F344 rats with PhIP (400 ppm)
or control diets for 20 weeks, and then sacrificed ani-
mals for histomorphologic examination at the ages of
25, 45, and 65 weeks. Animals treated with PhIP
showed significantly more inflammation (P = .002,
> .001, and .016 for 25, 45, and 65 weeks, respectively)
and atrophy (P = .003, > .001, and .006 for 25, 45, and
65 weeks, respectively) in their prostate glands relative
to controls. Prostatic intraepithelial neoplasia (PIN)
occurred only in PhIP-treated rats. PIN lesions arose in
areas of glandular atrophy, most often in the ventral
prostate. Atypical cells in areas of atrophy show loss of
glutathione S-transferase P immunostaining preceding
thedevelopment ofPIN.Noneof the animals in this study
developed invasive carcinomas, differing from those in
previous reports. Overall, these findings suggest that
the pathogenesis of prostatic neoplasia in the PhIP-
treated rat prostate proceeds from inflammation to
postinflammatory proliferative atrophy to PIN.
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Introduction
Prostate cancer is the second leading cause of cancer
deaths in men in the United States. Specific etiologies
remain unknown, but there have been associations with
dietary factors such as the consumption of red meat and
saturated fats [1]. Interestingly, prostate cancer rates are
extremely low in Asia, particularly in China [2]. Although it is
not known whether inherited or environmental factors play
primary roles, several associations have been made. Emi-
grants from eastern countries to the west approach western
rates for prostate cancer within one generation, potentially
correlating with the adoption of a ‘‘western diet’’ [3] Autopsy
studies of American andChinesemen showadistinct difference
in prostatitis, with extremely high rates in Americans and
essentially no inflammation in Chinese [4–6]. Several experi-
mental associations between prostatic inflammation and pros-
tate cancer risk have been made recently [7,8].
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP)
has been implicated as a major mutagenic heterocyclic amine
in the human diet [9]. We have shown that PhIP forms DNA
adducts in prostate epithelial cells and induces mutations in
the rat prostate, mammary gland, and intestines when admin-
istered experimentally [10].
It has been reported that roughly 50% of Fischer F344 male
rats treated with PhIP at 1 year of age develop invasive prostate
carcinoma [11], and studies note a high incidence of ‘‘atypical
hyperplasia.’’ Histologic images of PhIP-induced prostate can-
cers are difficult to compare to histomorphologic images of
human prostate carcinoma. To characterize the progression
of prostatic neoplasia and to compare the morphology and
biology of PhIP-induced prostate cancers to those of human
diseases, we sought to study the early and intermediate time
points in these animals. We also sought to study control ani-
mals of the same ages and housed under identical conditions.
Methods
Animal Treatment
Male Fischer F344 rats (Simonsen Laboratories, Gilroy, CA)
were housed in an Association for Assessment of Laboratory
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Animal Care (AALAC)-accredited Lawrence Livermore Na-
tional Laboratory Animal Care and Use Facility and were
treated according to the ‘‘Guide for the Care and Use of Labo-
ratory Animals’’ (Laboratory Animal Resources, National
Research Council), with the approval of the Institutional
Animal Use and Care Committee. Forty rats at 5 weeks of
age were fed PhIP (Toronto Research Chemicals, Ontario,
Canada) in the diet for 20 weeks. Animals were weighed
weekly throughout the study. A PhIP dosing schedule, as
described in Shirai et al. [12], was chosen because it is
the minimum dose shown to cause prostate carcinoma. For
the first 13weeks (of a planned20weeks), PhIPwas fed to the
animals at 400 ppm in a certified basal diet (18% protein
rodent diet; Harlan Teklad Global, Madison, WI). However,
due to weight loss and poor health in the animals, PhIP
content was reduced to 200 ppm for the final 7 weeks. Forty
controls received a basal diet without the addition of PhIP. At
25 weeks, 10 PhIP-dosed and 10 control animals were
euthanized. Their urogenital and other grossly abnormal
tissues were isolated and fixed in 10% neutral-buffered
formalin for histologic examination. The remaining animals
were all returned to a regular basal diet, with euthanasia and
histologic examination at 40 and 60 weeks after treatment
(45 and 65 weeks of age). Historically, it has been reported
that over 50% of animals have invasive tumors at 60 weeks
[12]. The purpose of using intermediate time points, as well
as careful examination of nontumorous rats at 65 weeks,
was to characterize precancerous histomorphology.
Histology
Necropsy tissues, including those of the prostate, urethra,
bladder, seminal vesicles, testes, and bulbourethral glands,
were collected. Additional tissues were collected where
possible, including tissues from the intestines, lungs, liver,
kidneys, and pancreas. All tissues were fixed overnight in
neutral-buffered formalin and then transferred to 70% eth-
anol before processing. Tissues were paraffin-embedded
using standard histology protocols and sectioned at 4 mm.
The resulting sections were stained with hematoxylin and
eosin (H&E) and examined under light microscopy. Tissue
blocks containing the majority of prostate tissues, particularly
of the ventral, dorsal, and lateral glands, were identified for
serial step sectioning. Additional levels through these blocks
were mounted on plus-coated slides (Fischer), with five
alternating levels stained with H&E for morphologic analysis.
Immunohistochemistry
Immunohistochemistry was performed on 4-mm sections
mounted on plus-coated slides. For antigen retrieval, slides
were incubated in 10mMcitrate at 100jC. Primary antibodies
were incubated overnight at room temperature in phosphate-
buffered saline. We used the following primary antibodies:
rabbit monoclonal anti–Ki-67 (1:1000; LabVision, Fremont,
CA), rabbit polyclonal serum anti–glutathione S-transferase
k (GSTk) (1:400, 354212; Calbiochem, San Diego, CA), and
mouse monoclonal anti-Cox2 (1:250, 236004; Calbiochem).
Secondary antibodies and detections were performed using
the biotinylated secondary antibody and the EnVisionHRP kit
(DAKO, Carpenteria, CA), following the manufacturer’s
instructions. Histologic images were captured on a Zeiss
Axioskop light microscope and photographed with the Zeiss
AxioCam digital camera (Zeiss, Thornwood, NY).
Quantitation
The serial step sections of the ventral, dorsal, and lateral
glands, and sections of the anterior prostate gland were
examined by investigators blinded to the treatment group.
In each, the total volume of any gland presenting with
inflammation, atrophy, atypia, or prostatic intraepithelial neo-
plasia (PIN) was estimated by adding and averaging the
slide surface areas with these characteristics. In general,
the percentage of the affected part of the gland was given
to the nearest 5%. Inflammation was scored if there was
luminal abscess or if there was evident periepithelial or intra-
epithelial infiltration of any inflammatory cells (mononuclear
or segmented neutrophils). Often, this was accompanied
by an increased surrounding stromal thickness. Atrophy
was defined as a flattened epithelial cell lining, with individual
cells displaying a lateral width greater than basal-to-apical
height. Areas of atypia were defined as foci of cells with
increased nuclear size and hyperchromasia in the absence
of inflammation. There were areas of atypia that were di-
rectly associated with inflammation, but these were not
counted in quantitative analyses. The goal was to quantitate
potential preneoplastic foci, rather than epithelial reaction
to inflammation, which was separately quantitated. Areas of
PIN were defined as multiple cell layers with loss of cellular
polarity and with evidence of focality and proliferation. Areas
of proliferation remaining in a single cell layer were not de-
fined as PIN.
Statistical analysis was performed using Graph Pad
Prism software, version 4.0.3 (Graph Pad, San Diego, CA ).
Unpaired nonparametric t-test was applied to each data
set for each of the quantitated characteristics. The resulting
P values are recorded above each pair of compared data
sets. The data are represented in the 25th to 75th percen-
tiles, and medians were plotted as shown in Figure 1.
Results
Animal Treatment
During the study, PhIP-dosed rats consistently gained
less weight than control animals. After 13 weeks of dosing
at 400 ppm, the rats began to lose weight. Consequently,
PhIP dosewas reduced to 200 ppm for the remaining 7weeks
of dosing. After PhIP treatment had been completed, the
growth rate of PhIP-treated animals became the same as
that of controls, but these rats remained smaller than con-
trols. At week 20, at the end of treatment, the mean body
weight of PhIP-dosed animals was 191(± 30) g compared
to 413(± 25) g in controls. By week 40, treated rats had
gained slightly more than controls, with a mean body weight
of 287(± 42) g compared to 479(± 25) g in controls. By
week 60, the PhIP-dosed rats appeared to have the same
mean growth rate as that of untreated controls, although
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they did not ‘‘catch up’’ or grow at an accelerated rate [336(±
39) g for treated rats vs 525(± 37) g for controls]. In addition,
10 PhIP-dosed animals and 2 control animals died or were
euthanized due to deteriorating health before the termination
of the study.
Prostatic Histomorphology
Inflammation in the PhIP-treated rat prostate was the
earliest and most obvious change, compared that in the
control group (Figure 1A). In one rat that died during PhIP
treatment, the prostatic epithelium was discontinuous, with
areas of epithelial loss or denudation. These areas were
accompanied by inflammation and luminal debris. Inflam-
mation was found in all prostatic glands, but was least prom-
inent in the anterior or coagulating gland. Inflammation
persisted after the discontinuation of PhIP treatment, and
epithelial layers at all scheduled time points were intact, even
in areas of luminal microabcess. Many areas of inflamma-
tion were accompanied by reactive stromal proliferation,
resulting in a distinct thickening of the thin muscular layer
surrounding individual glands. These proliferations did not
appear to overgrow the reactive process or to become neo-
plastic, as has been reported in some mouse models of
prostate cancer [13]. Inflammation was seen focally in many
of the control animals, but involved fewer glands and was
generally mildest. Whereas the experimental animals had
dense exudative luminal content, the control animals had
only mild exudates with scattered luminal neutrophils. Inflam-
mation was most persistent in the dorsal and lateral glands,
and was second most persistent in the ventral prostate.
Over the time course from 25 to 65 weeks, inflammation de-
creased as atrophy increased. This was predominantly due
to decreased inflammation in the ventral prostate and the
corresponding expanded zones of atrophy.
Large areas of glandular atrophy, particularly those affect-
ing the ventral prostate, were seen in all treated animals.
Nontreated animals also appeared to be prone to glandular
atrophy, particularly in the ventral prostate, but with less
involved areas of the prostate (Figure 1B). Interestingly, only
in treated animals was proliferation seen to be interspersed
within areas of atrophy, and PIN lesions seen in animals
scheduled for late sacrifice (45 and 65 weeks) occurred in
Figure 1. Quantified changes in PhIP and control prostate glands. Overview of histologic changes in PhIP-treated rats (solid bars) and control rats (hatched bars).
The median (horizontal line), 25th to 75th percentiles (column boxes), and range (tail bars) of the percentages of prostate glands involved are plotted for the groups
at each time point (25, 45, and 65 weeks of age). An unpaired nonparametric t-test was applied to the groups at each time point, and the resulting P values are
shown above the data bars. The t-test could not be applied to the PIN data because all of the values in many of the columns were zero. The percentages of the
glands showing inflammation, atrophy, atypia, and PIN are shown in (A), (B), (C), and (D), respectively.
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areas of atrophic ventral prostate in the majority of cases
(Figure 2). A single animal in the 25-week group developed a
PIN lesion. Eight (25%) PhIP-treated animals examined by
histopathology had foci meeting criteria for PIN (n = 32).
PIN lesions seen in PhIP-treated rats were characterized
by a cribriform architecture with well-differentiated epithelial
cells forming solid bridges and circular apolar lumina. The
lesions filled the glandular lumen but did not show distension
with foci of stromal interruption. These features would be, at
least, grade 2 (of 4) and would be, at most, grade 3 (of 4) in
published grading criteria for PIN in rodents [14]. There was
some variation in the extent of PIN between animals, with two
animals showing PIN of grades 1 to 2 (of 4). Six animals had
grade 3 lesions, and three of these had more than one foci.
No invasive carcinoma was seen in any of the animals.
There were areas of inflammation-induced stromal prolifera-
tion and high levels of ‘‘inflammatory atypia’’ (atypia of repair).
Consistent with the low rate of prostatic neoplasia, we also
observed a lower-than-expected rate of intestinal neoplasia.
Not all animals were examined, but of the 20 animals ex-
amined with at least a segmental histology of the intestine,
only one had a full-fledged polypoid adenoma, and only two
others had areas of early adenomatous changes.
Immunohistochemistry
Ki-67 staining confirmed a high rate of proliferation in areas
of PIN with a 15% to 20% nuclear positivity (Figure 2B).
All other areas of the glands showed a nuclear positivity from
1–2% in normal noninflammed areas to 5–10% in areas with
inflammation (Figure 3B) or in areas without inflammation
but with aberrant cytologic features (Figure 4). This is consis-
tent with the findings of mitotic figures in these foci. There was
no significant increase in apoptosis in these areas.
Figure 2. PIN arises from atrophy in the PhIP-treated rat prostate. H&E stain
of the ventral prostate at 65 weeks (A). Within the atrophic glands, occasional
areas of proliferation with loss of polarity and cells forming cribriform spaces
and Roman bridges are seen. The high proliferation of these areas is
confirmed by a Ki-67 immunostain (B) showing a marked increase in the
percentage of cell staining (nuclear stain) in these regions.
Figure 3. Atypical proliferations arise in an inflamed prostate.Within areas of a
markedly inflamed prostate, foci of the proliferative epithelium are seen. A low-
power view of the dorsal and lateral prostate glands (A) shows a segmental
area of inflammation (Infl) and another area of atrophy (Atr). The urethra (U)
is at the top right, and the box indicates the location of high magnification
seen in (B). The high magnification shows epithelial proliferation with cellular
loss of polarity and cytologic atypia. These areas were not regarded as neo-
plastic, as similar areas in a variety of sites are known to resolve completely
with resolution of the inflammation. This type of lesion is often referred to as
inflammatory atypia.
PhIP Rat Prostate Borowsky et al. 711
Neoplasia . Vol. 8, No. 9, 2006
GSTk immunostaining showed the highest expression
in prostate basal cells in all glands, and moderate to low
expression was seen in the epithelium. GSTk immuno-
staining confirmed that PIN lesions, specific cell populations
in areas of atrophy, and focal areas with atypical cells also
showed loss of GSTk (Figure 5B). All of the PIN lesions
examined yielded negative results, although some of the PIN
lesions were not present in the tissue sections obtained for
immunostaining and could not be evaluated. The precise
relationship between GSTk-negative atypical cells and
the development of PIN was difficult to estimate. Prostate
samples did not show the two populations in continuity, nor
was there a continuous spectrum of lesions between the
polarized single layer of atypical cells and the fully developed
PIN lesions.
Cox2 immunostaining showed that there was variability in
the rat prostate with high expression in the vas deferens
epithelium, moderate expression in the seminal vesicle
epithelium, and variable expression in the prostate gland.
Consistent with previous reports, the uninflammed and non-
atrophic ventral prostate had very low/negative expression
[15]. Interestingly, the atrophic ventral prostate maintained
a very low expression. Some areas of atypical cells, particu-
larly those with negative GSTk, retained a low/weak expres-
sion of Cox2 (Figure 5C). Other areas of atypia and areas
of PIN had higher Cox2 expression (Figure 5D).
Figure 4. PhIP induces prostate epithelial proliferation. The PhIP-treated prostate shows abnormal proliferation, with mitoses (indicated by arrows) compared to
the prostate of a control vehicle-treated animal (on the right). Both panels present ventral prostate glands from rats. Images from formalin-fixed paraffin-embedded
4-m tissue sections stained with H&E were obtained on a Zeiss Axioskop equipped with a Zeiss AxioCam digital camera using the Axiovision acquisition software.
Scale bars indicate actual size (lower right of each panel).
Figure 5. Atypical cells in the PHIP-treated rat prostate lose GSTp expression; Cox2 expression varies. The atypical cells shown (arrows in A) have abundant
cytoplasm and nuclei, with single prominent nucleoli. Basal cells can be seen interspersed among these cells and are highlighted by GST immunostain (B). Cox2
(C) is slightly reduced in the same cells, but is immunopositive. Cox2 internal positive control (vas deferens) is strongly positive (inset). In different areas (D), Cox2
is increased in atypical foci.
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Leydig Cell Tumors
All rats in the 65-week group (both treated and controls)
showed testicular Leydig cell hyperplasias, with several rats
in both groups displaying very large areas that might be
regarded as Leydig cell tumors (Figure 6). These were char-
acterized by well-differentiated Leydig cells of the testicular
stroma, with abundant cytoplasm and focal crystalloid-
like cytoplasmic inclusions. This is a common finding in
Fischer rats [16]. The testicular tubules were normal, with
good maturation of germ cells. The amount of testosterone
production and serum testosterone levels is not known. A
few animals in both treated and control groups at 45 weeks
had focal mild Leydig cell hyperplasia. Animals in the
25-week group had no evidence of testicular pathology.
Discussion
For the first time, we carefully examined the prostate pathol-
ogy of precancer stages in the PhIP rat model. In our study, it
seems clear that PhIP is capable of inducing a rapid and
persistent prostatic inflammation. The mechanism of inflam-
mation induced by PhIP is not precisely clear, but appears
to involve a specific toxicity to the prostatic epithelium. This
may result in an immediate disruption of epithelial barrier
and subsequent inflammation. However, this does not ade-
quately explain the persistence of inflammation. In some
areas without inflammation, atypical proliferation is seen. In
areas near inflammation, it is similar to the epithelial re-
action seen in any inflamed mucosa. The areas that continue
to display atypia and proliferation in the absence of inflam-
mation suggest that there is a permanent change in the
epithelium induced by PhIP. It is not clear whether this is
the result of specific mutations or selection based on pro-
moter methylation induced by an inflammatory or a post-
inflammatory biologic niche. In our studies, we show that
there are populations of cells that downregulate GSTp, a
gene known to be downregulated in the prostate epithelium
by promoter methylation.
It was expected, based on previous reports, that roughly
half of the 65-week PhIP-treated animals would develop
invasive carcinomas. None did. It may be because the
animals received an effectively decreased dose compared
to those in previous publications. Storage conditions and
the source and grade of the PhIP reagent were identical to
those previously reported, but there may still have been
unanticipated degradation of the chemical or a problem with
the specific production run or lot. We believe that this is
unlikely in light of an obvious effect on animal health (as in-
dicated by animal weight and the 10 animals that became ill
during treatment). Furthermore, we have found in previous
high-performance liquid chromatography analyses that PhIP
is very stable. In the context of histologic findings, however,
additional hypotheses should be considered. Colony and
housing conditions may contribute to the levels of exposure
of the animals to specific bacterial flora, and these can
contribute to prostatic inflammation. In the context of our ex-
periments, perhaps a cleaner or flora-shifted colony resulted
in decreased penetrance of the invasive cancer phenotype.
Regardless of the absence of invasive cancer, it should be
noted that several animals developed definitive PIN lesions
and that PIN lesions are never seen in rats or mice as spon-
taneous lesions in untreated or nongenetically engineered
prostates. It is possible that the effective dose of PhIP in our
study was higher than those in previous reports. Mechanis-
tically, it may be that a higher dose would result in a higher
specific prostate epithelial toxicity and that this would re-
duce the pool of potentially neoplastic cells. This would imply
that a specific subset of cells in the prostate is susceptible
to both PhIP toxicity and PhIP-initiated carcinogenesis.
It also is hard to compare the reported invasive pheno-
types in the literature because few histologic images are
available. In our study, there were areas of profound inflam-
mation with stromal reaction, sclerosis, and significant epi-
thelial cytologic atypia (atypia of repair). Some of these might
mimic invasion, out of the context of the glandular architec-
ture. Further study is needed to determine if the PIN lesions
seen in fact progress to invasive carcinomas. It will be useful
to characterize the histomorphology of invasive carcinomas
occurring in PhIP-treated rats and to compare their morphol-
ogy to human prostate cancers. This comparative pathology
is an essential part of validating the model for further study,
including preclinical trials.
Aging F344 rats develop PIN lesions identical to those
seen in this study, although at much lower rates and at older
ages [17]. F344 rats, studied at 2 years of age, showed the
same kind of cribriform proliferative PIN lesions in areas of
atrophy that we saw in this study. Four percent of the rats in
the study developed ‘‘adenomas or carcinomas,’’ with rats
from 12 different potential carcinogen treatment groups and
untreated control groups having the same rates. Similarly,
another strain, the ACI/seg HapBR rat, which was examined
between 2 and 3.5 years of age, had a high incidence of PIN-
like lesions and invasive carcinomas [18]. These studies
suggest that, first, inflammation and atrophy precede PIN,
Figure 6. F344 rats develop Leydig cell hyperplasia. Rats in both control and
PhIP-treated groups developed Leydig cell hyperplasia with high penetrance.
Patchy areas of Leydig cell hyperplasia, varying in size, were seen in amajority
of animals at the 65-week time point. This example shows a relatively large
patch of Leydig cells (Ley) adjacent to two seminiferous tubules (Tub).
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even in the absence of amutagen. Second, these PIN lesions
likely can progress to invasive carcinoma (although no evi-
dence of metastasis was found). Finally, these data support
a hypothesis that PhIP acts primarily by increasing inflam-
mation and subsequent atrophy in the rat prostate. Increased
inflammation and atrophy, as documented in our data, result
in increased rates and decreased latency of neoplasia.
The finding that F344 rats have Leydig cell hyperplasia
and Leydig cell testicular tumors may explain the overall
susceptibility of this strain to prostate tumorigenesis. One
group compared susceptibility across common laboratory
strains and measured testosterone and estradiol levels.
Interestingly, F344 rats had the second highest testosterone
levels at 54 weeks and the highest estradiol levels. Only
spontaneously hypertensive rats had testosterone levels
significantly higher than those of other strains, and these
and ACI rats appeared to be most sensitive to prostatic neo-
plasia [19]. This remains an important consideration when
modeling endocrine-responsive tissues and cancers.
We and others have shown that PhIP is capable of form-
ing DNA adducts and inducing DNAmutations in the prostate
of F344 rats [10,11,20,21]. It has generally been proposed
that low levels (relative to the experimental treatment in
rats) of PhIP in the western diet might induce low levels of
mutations in the human prostate epithelium, which might
accumulate and confer a selective advantage on epithelial
cells, ultimately resulting in cancer. Other groups have pro-
posed that PhIP is a potent endocrine hormone analog
[22,23]. Several groups have used the rat model to test the
effect of potential adduct-preventing andmutation-preventing
agents [10,24–26]. This is a highly useful surrogate end-
point that can be quantified with high specificity at early time
points, before morphologic changes arise. It is not precisely
known whether these adducts and mutations will lead to the
progressive acquisition of cancer cell characteristics. In part,
it was the goal of this study to try to more clearly make this
association. Instead, the data suggest that adduct mutations
are either unrelated to neoplastic progression or, alterna-
tively, may cause or contribute primarily to inflammation, with
neoplasia occurring secondary to inflammation rather than
to mutation.
Increasing evidence suggests that prostatic inflammation
and the resulting reactive processes are highly associated
with cancer risk. The concept of prostatic inflammatory
atrophy has been proposed to be a prostate cancer precursor,
or at least to increase susceptibility to further changes, re-
sulting in prostate cancer [5,8]. A number of molecular cor-
relates with postinflammatory atrophic morphology have
been established, including promoter methylation and gene
silencing for GSTp and Cox2 [7,25,27,28]. We have shown
that benign prostate lesions are sometimes accompanied
by changes in apoptosis mediator proteins [28].
Our interest in PhIP administration in rodents as a model
of human prostate carcinogenesis is chiefly based on clinical
epidemiology. The high meat and fat content in the western
diet, particularly in African Americans, may influence both
the development and the progression of prostate cancer. We
have previously demonstrated the exquisite sensitivity of the
prostate to PhIP. At a dose equivalent to one overcooked
hamburger fed to F344 rats, DNA adducts can be detected
in the prostate [10]. Our data suggest that PhIP-treated rats
will also help to characterize the role of prostate inflammation
in cancer initiation. In summary, we have shown that the
PhIP-treated rat is a useful model of human disease that is
suitable for testing prevention strategies targeting either
DNA adduct formation or prostate inflammation.
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